Drug Development, School of Medicine, Trinity College Dublin D02 R590, Ireland.
Drug Development, School of Medicine, Trinity College Dublin D02 R590, Ireland
J Neurosci. 2020 Apr 8;40(15):3104-3118. doi: 10.1523/JNEUROSCI.2346-19.2020. Epub 2020 Mar 3.
Krabbe's disease is an infantile neurodegenerative disease, which is affected by mutations in the lysosomal enzyme galactocerebrosidase, leading to the accumulation of its metabolite psychosine. We have shown previously that the S1P receptor agonist fingolimod (FTY720) attenuates psychosine-induced glial cell death and demyelination both and models. These data, together with a lack of therapies for Krabbe's disease, prompted the current preclinical study examining the effects of fingolimod in twitcher mice, a murine model of Krabbe's disease. Twitcher mice, both male and female, carrying a natural mutation in the galc gene were given fingolimod via drinking water (1 mg/kg/d). The direct impact of fingolimod administration was assessed via histochemical and biochemical analysis using markers of myelin, astrocytes, microglia, neurons, globoid cells, and immune cells. The effects of fingolimod on twitching behavior and life span were also demonstrated. Our results show that treatment of twitcher mice with fingolimod significantly rescued myelin levels compared with vehicle-treated animals and also regulated astrocyte and microglial reactivity. Furthermore, nonphosphorylated neurofilament levels were decreased, indicating neuroprotective and neurorestorative processes. These protective effects of fingolimod on twitcher mice brain pathology was reflected by an increased life span of fingolimod-treated twitcher mice. These findings corroborate initial studies and highlight the potential use of S1P receptors as drug targets for treatment of Krabbe's disease. This study demonstrates that the administration of the therapy known as fingolimod in a mouse model of Krabbe's disease (namely, the twitcher mouse model) significantly rescues myelin levels. Further, the drug fingolimod also regulates the reactivity of glial cells, astrocytes and microglia, in this mouse model. These protective effects of fingolimod result in an increased life span of twitcher mice.
克拉伯病是一种婴儿神经退行性疾病,受溶酶体酶半乳糖脑苷脂酶突变的影响,导致其代谢产物神经鞘氨醇的积累。我们之前已经表明,鞘氨醇 1-磷酸受体激动剂 fingolimod(FTY720)可减轻神经鞘氨醇诱导的神经胶质细胞死亡和脱髓鞘作用, 和 模型。这些数据,再加上缺乏克拉伯病的治疗方法,促使我们进行了当前的临床前研究,以检查 fingolimod 在抽搐小鼠(克拉伯病的一种小鼠模型)中的作用。抽搐的雄性和雌性小鼠均携带 galc 基因的天然突变,通过饮用水(1mg/kg/d)给予 fingolimod。通过使用髓鞘、星形胶质细胞、小胶质细胞、神经元、成神经细胞瘤和免疫细胞的标志物进行组织化学和生化分析,评估 fingolimod 的直接作用。还证明了 fingolimod 对抽搐行为和寿命的影响。我们的结果表明,与 vehicle 治疗的动物相比,用 fingolimod 治疗抽搐小鼠可显著挽救髓鞘水平,并且还调节星形胶质细胞和小胶质细胞的反应性。此外,非磷酸化神经丝水平降低,表明具有神经保护和神经修复作用。fingolimod 对抽搐小鼠脑病理学的这些保护作用反映在 fingolimod 治疗的抽搐小鼠寿命的增加上。这些发现证实了最初的研究结果,并强调了鞘氨醇 1-磷酸受体作为治疗克拉伯病的药物靶点的潜力。本研究表明,在克拉伯病(即抽搐小鼠模型)的小鼠模型中给予治疗药物 fingolimod 可显著挽救髓鞘水平。此外,该药物 fingolimod 还可调节该小鼠模型中神经胶质细胞、星形胶质细胞和小胶质细胞的反应性。fingolimod 的这些保护作用导致抽搐小鼠的寿命延长。